Immunovant falls as drug for thyroid eye disease fails late-stage trials

Hanall Biopharma

02/04/2026 14:53

** Shares of biotech firm Immunovant IMVT.O fall 5.6% to $23.69

** Co says its experimental drug, batoclimab, failed two late-stage trials

** Adds trials to test the drug for thyroid eye disease — an autoimmune condition that causes eye bulging and vision problems — missed main goals

** Says studies showed not enough patients had meaningful reduction in eye bulging after 24 weeks of treatment

** Patients improved more in the first 12 weeks on a higher dose than later on a lower dose, suggesting stronger antibody suppression may work better - Co

** IMVT says safety results in line with earlier studies, with no new issues reported

** Adds it will discuss next steps for batoclimab with partner HanAll Biopharma and stay focused on its other experimental drug IMVT-1402 for autoimmune diseases

** Including session's move, stock down ~6% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))